FAAS
VIRX

First Allied Advisory Services’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

First Allied Advisory Services’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-437
Closed -$43K – 1254
2018
Q1 		$43K Buy
+437
New +$74.9K ﹤0.01% 1153

Other funds holding VIRX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

First Allied Advisory Services's VIRX Position: Q2 2018 in Review

First Allied Advisory Services sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2018, closing a stake of 437 shares — an estimated $43K sold.

First Allied Advisory Services first reported a position in VIRX in Q1 2018 and held it in 1 quarter. The position peaked at $43K in Q1 2018. 50 funds tracked by Wall St. Rank hold VIRX as of Q2 2018.

  • First Allied Advisory Services reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
  • First Allied Advisory Services sold 437 Viracta Therapeutics, Inc. Common Stock shares in Q2 2018, an estimated $43K.
  • First Allied Advisory Services first reported a position in Viracta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 1 quarter.
  • First Allied Advisory Services's Viracta Therapeutics, Inc. Common Stock position peaked at $43K in Q1 2018.
  • 50 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2018.

Based on First Allied Advisory Services's 13F filing for Q2 2018, filed 8 Aug 2018.